Raymond James Financial Inc. Buys New Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Raymond James Financial Inc. acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 746,406 shares of the company's stock, valued at approximately $18,048,000. Raymond James Financial Inc. owned about 0.34% of Hims & Hers Health as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health in the fourth quarter worth $28,000. Raleigh Capital Management Inc. increased its position in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after acquiring an additional 1,100 shares during the period. Smartleaf Asset Management LLC raised its stake in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after acquiring an additional 1,413 shares during the last quarter. US Bancorp DE lifted its position in Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock worth $47,000 after acquiring an additional 1,508 shares during the period. Finally, Venturi Wealth Management LLC purchased a new stake in Hims & Hers Health during the 4th quarter valued at about $48,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 4,213 shares of the stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $29.98, for a total value of $126,305.74. Following the completion of the sale, the chief financial officer now owns 128,365 shares of the company's stock, valued at approximately $3,848,382.70. This trade represents a 3.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Andrew Dudum sold 36,460 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $27.09, for a total transaction of $987,701.40. Following the sale, the chief executive officer now directly owns 27,918 shares in the company, valued at approximately $756,298.62. The trade was a 56.63 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,015,547 shares of company stock worth $36,146,450. 17.71% of the stock is owned by corporate insiders.

Remove Ads

Hims & Hers Health Price Performance

NYSE HIMS traded up $1.90 during trading hours on Friday, reaching $34.77. The company's stock had a trading volume of 45,662,610 shares, compared to its average volume of 13,777,199. Hims & Hers Health, Inc. has a 1-year low of $11.20 and a 1-year high of $72.98. The company's 50-day moving average is $39.02 and its two-hundred day moving average is $28.55. The firm has a market capitalization of $7.72 billion, a price-to-earnings ratio of 79.02 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $481.14 million for the quarter, compared to analysts' expectations of $494.56 million. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on HIMS shares. Piper Sandler lifted their target price on Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a report on Tuesday, February 25th. Leerink Partners raised their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research report on Tuesday, February 25th. Truist Financial upped their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a "hold" rating in a report on Wednesday, February 26th. Morgan Stanley cut shares of Hims & Hers Health from an "overweight" rating to an "equal weight" rating and raised their target price for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Finally, Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $37.31.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.